These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8120869)

  • 1. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
    Ducharme Y; Brideau C; Dubé D; Chan CC; Falgueyret JP; Gillard JW; Guay J; Hutchinson JH; McFarlane CS; Riendeau D
    J Med Chem; 1994 Feb; 37(4):512-8. PubMed ID: 8120869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
    Delorme D; Ducharme Y; Brideau C; Chan CC; Chauret N; Desmarais S; Dubé D; Falgueyret JP; Fortin R; Guay J; Hamel P; Jones TR; Lépine C; Li C; McAuliffe M; McFarlane CS; Nicoll-Griffith DA; Riendeau D; Yergey JA; Girard Y
    J Med Chem; 1996 Sep; 39(20):3951-70. PubMed ID: 8831761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
    Hutchinson JH; Riendeau D; Brideau C; Chan C; Delorme D; Denis D; Falgueyret JP; Fortin R; Guay J; Hamel P
    J Med Chem; 1993 Sep; 36(19):2771-87. PubMed ID: 8410991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
    Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM
    J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
    Hamel P; Riendeau D; Brideau C; Chan CC; Desmarais S; Delorme D; Dubé D; Ducharme Y; Ethier D; Grimm E; Falgueyret JP; Guay J; Jones TR; Kwong E; McAuliffe M; McFarlane CS; Piechuta H; Roumi M; Tagari P; Young RN; Girard Y
    J Med Chem; 1997 Aug; 40(18):2866-75. PubMed ID: 9288168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
    Hutchinson JH; Riendeau D; Brideau C; Chan C; Falgueyret JP; Guay J; Jones TR; Lépine C; Macdonald D; McFarlane CS
    J Med Chem; 1994 Apr; 37(8):1153-64. PubMed ID: 8164257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational analysis of 5-lipoxygenase inhibitors: role of the substituents in chiral recognition and on the active conformations of the (methoxyalkyl)thiazole and methoxytetrahydropyran series.
    Lambert-van der Brempt C; Bruneau P; Lamorlette MA; Foster SJ
    J Med Chem; 1994 Jan; 37(1):113-24. PubMed ID: 8289184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
    Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
    J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
    Bird ; Bruneau P; Crawley GC; Edwards MP; Foster SJ; Girodeau JM; Kingston JF; McMillan RM
    J Med Chem; 1991 Jul; 34(7):2176-86. PubMed ID: 1648621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase.
    Crawley GC; Bird TG; Bruneau P; Dowell RI; Edwards PN; Foster SJ; Girodeau JM; McMillan RM; Walker ER; Waterson D
    J Lipid Mediat; 1993; 6(1-3):249-57. PubMed ID: 8395247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
    Lau CK; Bélanger PC; Dufresne C; Scheigetz J; Therien M; Fitzsimmons B; Young RN; Ford-Hutchinson AW; Riendeau D; Denis D
    J Med Chem; 1992 Apr; 35(7):1299-318. PubMed ID: 1313879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methoxyalkyl thiazoles: a novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase.
    McMillan RM; Bird TG; Crawley GC; Edwards MP; Girodeau JM; Kingston JF; Foster SJ
    Agents Actions; 1991 Sep; 34(1-2):110-2. PubMed ID: 1793013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on 5-lipoxygenase inhibitors. I. Synthesis and 5-lipoxygenase-inhibitory activity of novel hydroxamic acid derivatives.
    Yatabe T; Kawai Y; Oku T; Tanaka H
    Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):966-72. PubMed ID: 9658575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
    Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
    J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
    Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
    Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3- methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor.
    Belanger P; Maycock A; Guindon Y; Bach T; Dollob AL; Dufresne C; Ford-Hutchinson AW; Gale PH; Hopple S; Lau CK
    Can J Physiol Pharmacol; 1987 Dec; 65(12):2441-8. PubMed ID: 2835137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
    Gillard J; Ford-Hutchinson AW; Chan C; Charleson S; Denis D; Foster A; Fortin R; Leger S; McFarlane CS; Morton H
    Can J Physiol Pharmacol; 1989 May; 67(5):456-64. PubMed ID: 2548691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
    Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
    Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors.
    Fischer L; Szellas D; Rådmark O; Steinhilber D; Werz O
    FASEB J; 2003 May; 17(8):949-51. PubMed ID: 12670876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.